13,321 Shares of Abbott Laboratories $ABT Bought by Sawyer & Company Inc

Sawyer & Company Inc purchased a new stake in Abbott Laboratories (NYSE:ABT) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 13,321 shares of the healthcare product maker’s stock, valued at approximately $1,317,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in shares of Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares during the last quarter. State Street Corp lifted its holdings in shares of Abbott Laboratories by 1.7% in the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after purchasing an additional 1,350,766 shares in the last quarter. Bank of America Corp DE purchased a new position in shares of Abbott Laboratories during the second quarter valued at approximately $1,603,607,000. Deutsche Bank AG boosted its position in shares of Abbott Laboratories by 18.6% during the second quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock valued at $1,515,963,000 after buying an additional 2,614,965 shares during the last quarter. Finally, Legal & General Group Plc bought a new stake in Abbott Laboratories during the second quarter worth $1,082,524,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported third-quarter sales of $13.01 billion, up 14.5% year over year and slightly above consensus estimates. Comparable sales increased 7%, while adjusted diluted EPS rose to $1.42 from $1.30 a year earlier. Abbott Reports Third-Quarter 2026 Results
• Positive Sentiment: The company reaffirmed its full-year adjusted EPS guidance, and expanding margins plus new product approvals support Abbott’s longer-term profitability outlook. Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
• Positive Sentiment: Abbott received a European CE Mark for its Cologuard Plus colorectal cancer test, expanding its diagnostics offering and potential market reach in Europe. Abbott Secures Europe CE Mark for Colorectal Cancer Test
• Neutral Sentiment: Abbott plans to separate its global Nutrition business—including Similac, Ensure, Glucerna, PediaSure and Pedialyte—into an independent, publicly traded company through a tax-free distribution to shareholders by the end of 2027. Management expects the move to let both businesses pursue more focused growth strategies, but execution, transaction costs and the eventual loss of Nutrition revenue remain important considerations. Abbott Announces Nutrition Business Separation
• Negative Sentiment: Adjusted third-quarter EPS of $1.42 narrowly missed the Zacks consensus estimate of $1.43, making the earnings headline less favorable despite revenue growth. Abbott Misses Q3 Earnings Estimates
• Negative Sentiment: Abbott lowered its 2026 sales-growth forecast, citing weakness in its Medical Devices business. The softer outlook raised concerns about near-term growth momentum and was the primary fundamental pressure on ABT. Abbott Lowers 2026 Sales Growth Forecast

Abbott Laboratories Stock Performance

Shares of ABT stock traded down $3.92 during trading on Wednesday, hitting $98.53. The company’s stock had a trading volume of 14,038,442 shares, compared to its average volume of 11,288,529. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The company has a market cap of $170.49 billion, a PE ratio of 31.95, a P/E/G ratio of 1.93 and a beta of 0.59. The business has a fifty day moving average of $105.68 and a 200-day moving average of $98.30. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $132.02.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting analysts’ consensus estimates of $1.42. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. The business had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. During the same period last year, the company posted $1.30 earnings per share. Abbott Laboratories’s quarterly revenue was up 14.5% compared to the same quarter last year. As a group, research analysts anticipate that Abbott Laboratories will post 5.53 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.6%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Analyst Ratings Changes

ABT has been the subject of a number of analyst reports. Barclays assumed coverage on Abbott Laboratories in a research report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price target for the company. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a research note on Thursday, August 13th. UBS Group cut their price objective on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. TD Cowen reiterated a “buy” rating and issued a $135.00 target price on shares of Abbott Laboratories in a research note on Friday, October 16th. Finally, Robert W. Baird assumed coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price for the company. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $118.88.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.